ClinicalTrials.gg
TerminatedNCT01602328ACT-AKIUpdated Aug 6, 2014

A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

A Phase 2 interventional study of AC607 and Vehicle Only in Acute Kidney Injury, sponsored by AlloCure Inc.. Terminated at 31 sites in 2 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2014-08-06.

Sponsored by AlloCure Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 370 studies in Acute Kidney Injury with a site in United States — 72 open to participants now, 88 under way, 9 of them phase 3. Acute Kidney Injury · United States.

Enrollment
77th of 237
156 · median 67
Started
2012
with 7 others
Phase 2
54 of 370
11 open now
Registered
72nd of 370
by date

Among the 370 studies in Acute Kidney Injury with a site in United States, this one is the 77th largest by enrollment of the 237 interventional ones that give a count, is one of 8 that started in 2012, is one of 54 in phase 2, and was the 72nd registered.

Acute Kidney Injury

1,691 studies on the registry are indexed under Acute Kidney Injury; 393 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

72 of the 370 studies in Acute Kidney Injury with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies in Acute Kidney Injury with a site in United States, or all of them as a file.
02

Study summary

Subjects entering the study will have undergone cardiac surgery. Those who experience kidney injury within 48 hours of their surgery will be enrolled into the study. Once enrolled, subjects will receive a single administration of AC607 or placebo. Kidney recovery will be evaluated over the subsequent 30 days and death or the need for dialysis will be evaluated within 90 days of dosing. After 90 days (evaluation period), subjects will enter a 3-year extension phase of the study to monitor safety and long-term outcomes (follow-up period).

Read the detailed description

The study will enroll post-cardiac surgery subjects (CABG and/or valve) with laboratory evidence of AKI within 48 hrs of removal from cardiopulmonary bypass. Subjects will be randomly assigned (1:1 ratio) to treatment with a single administration of AC607 or placebo (approximately 100 subjects per group).

Safety and efficacy assessments will be performed daily during the post-operative hospital stay from the day randomized into the study until discharge, at 30 days, and at 90 days after study drug administration (evaluation phase). Safety and long-term clinical outcomes will be assessed at 6, 12, 24 and 36 months (long-term follow-up phase).

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • Acute Kidney Injury
  • Acute renal failure
  • Human mesenchymal stem cells
  • Allogeneic stem cells
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 21 years
  • Had cardiovascular surgery utilizing cardiopulmonary bypass
  • Have a pre-operative (baseline) serum creatinine value collected within 30 days of surgery (if multiple laboratory results are available within this time window, the most recent serum creatinine value prior to surgery will be used to establish the baseline)
  • Willing and able to comply with visit schedule and study procedures including post-hospitalization discharge follow-up
  • Ability to give or have a legally acceptable representative do so for them
  • Have AKI defined as ≥ 0.5 mg/dL rise in serum creatinine from baseline within 48 hours of removal from cardiopulmonary bypass

Exclusion criteria

Exclusion Criteria:

  • Active cancer and/or receiving active treatment for cancer, with the exception of squamous cell or basal cell carcinoma of the skin
  • Had surgery for thoraco-abdominal aortic aneurysm (TAAA)
  • Currently participating in another interventional drug or device clinical study
  • Prisoner or other detainee
  • Has a current medical condition that would preclude or compromise femoral artery catheter placement
  • Has an intra-aortic balloon pump (IABP) in place within 2 hours of catheter placement
  • Has a ventricular assist device (VAD) or extracorporeal membrane oxygenation (ECMO) in place at the time of the study catheter placement
  • Prior history of solid organ or bone marrow transplant
  • Stage 5 CKD or currently on dialysis
  • Are expected to receive dialysis within 24 hours of enrollment or dosing
  • Had a complication during surgery or post-operatively that, in the opinion of the principal investigator (PI), significantly increases the risk of complications to the subject and therefore precludes dosing the subject
  • Are pregnant or lactating. A woman with may be tested for pregnancy at the discretion of the PI.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
156 participants (actual)

Study arms

  • Active comparator
    AC607

    Treatment with AC607

    Biological: AC607

  • Placebo comparator
    Placebo

    Treatment with Placebo

    Biological: Vehicle Only

Interventions

  • BiologicalAC607

    AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight

    Also known as: allogeneic bone marrow-derived human mesenchymal, stem cells

  • BiologicalVehicle Only

    The dose will be calculated and recorded in the same way as for AC607.

06

What researchers measure

Primary outcomes

  1. Time to Kidney Recovery defined as a post-operative serum creatinine return to pre-operative baseline values.

    The first occurrence of a post-dosing serum creatinine level that is equal to or less than the subject's pre-operative baseline level.

    Time frame: Within 30 days of dosing.

Secondary outcomes

  1. All-Cause Mortality or Dialysis (composite endpoint).

    Time frame: Subjects who died or received dialysis within 30 and 90 days after dosing.

07

Study locations

31 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • University of California, San Diego
    San Diego, California 92103, United States
  • Stanford Hospital and Clinics
    Stanford, California 94305-2299, United States
  • MedStar Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Rutgers Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08903, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Lankenau Medical Center
    Wynnewood, Pennsylvania 19096, United States
  • UTHealth, The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Fletcher Allen Health Care - Renal Services
    Burlington, Vermont 05401, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • CAMC Clinical Trials Center
    Charleston, West Virginia 25304, United States
  • Foothills Medical Centre
    Calgary, Alberta T2N 2T9, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • University of Manitoba - St. Boniface Hospital
    Winnipeg, Manitoba R2H 2A6, Canada
  • CDHA Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia B3H 3A7, Canada
  • McMaster - Hamilton General Hospital / TAARI
    Hamilton, Ontario L8L 2X2, Canada
  • London Health Sciences Centre, University Hospital
    London, Ontario N6J 1S1, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Montreal Heart Institute
    Montreal, Quebec H1T 1C8, Canada
  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec
    Quebec, G1V 4G5, Canada
08

References and documents

Publications

  • Zhao L, Hu C, Zhang P, Jiang H, Chen J. Preconditioning strategies for improving the survival rate and paracrine ability of mesenchymal stem cells in acute kidney injury. J Cell Mol Med. 2019 Feb;23(2):720-730. doi: 10.1111/jcmm.14035. Epub 2018 Nov 28. PubMed 30484934 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Jun 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2012
First posted
May 21, 2012
Start
Jun 2012
Primary completionActual
Jun 2014
CompletionActual
Aug 2014
Last update
Aug 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01602328
Lead sponsor
AlloCure Inc.
Responsible party
Sponsor
First posted
May 21, 2012
Start date
Jun 2012
Primary completion
Jun 2014
Completion
Aug 2014
Last update
Aug 6, 2014

Study contacts

Viken Paragamian
study director

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem Cell

Start the discussion